Lynn Y.L. Huang - Concepedia

Author

Lynn Y.L. Huang

Development Center for Biotechnology

Also Known As

Lynn Huang, Lynn Y. Huang, Lynn Y. L. Huang, Lynn Y.L. Huang, Lynn YL Huang

Publications

232

Citations

H-Index

Concepts

All Affiliations

Development Center for Biotechnology National Chiayi University Cornell University

About

Lynn Y.L. Huang is an author at Development Center for Biotechnology specializing in medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	5	5	114
2	Cell Biology	3	3	74
3	Engineering	1	1	15
4	Biochemistry	1	1	15
5	Biomolecular Engineering	1	1	15

Lynn Y.L. Huang

Publications

232

Citations

H-Index

Page 1

	Year	Citations
Protein Kinase Cϵ Mediates Polymeric Fibronectin Assembly on the Surface of Blood-borne Rat Breast Cancer Cells to Promote Pulmonary Metastasis Lynn Y.L. Huang, Hung-Chi Cheng, Richard Isom, Journal of Biological Chemistry	2008	43
Discovery of 4-Aryl-<i>N</i>-arylcarbonyl-2-aminothiazoles as Hec1/Nek2 Inhibitors. Part I: Optimization of in Vitro Potencies and Pharmacokinetic Properties Ying-Shuan E. Lee, Shih‐Hsien Chuang, Lynn Y.L. Huang, Journal of Medicinal Chemistry	2014	39
Characterization of the biological activity of a potent small molecule Hec1 inhibitor TAI-1 Lynn Y.L. Huang, Ying-Shuan Lee, Jiann‐Jyh Huang, Journal of Experimental & Clinical Cancer Research	2014	36
Conditional knockout of fibronectin abrogates mouse mammary gland lobuloalveolar differentiation Keyi Liu, Le Cheng, Andrea Flesken‐Nikitin, Developmental Biology FibrosisDevelopmental BiologyConditional KnockoutMammary GlandMatrix Biology	2010	35
Inhibition of Hec1 as a novel approach for treatment of primary liver cancer Lynn Y.L. Huang, Chia‐Chi Chang, Ying-Shuan Lee, Cancer Chemotherapy and Pharmacology Primary Liver CancerOncologyHepatologyMedicineHepatobiliary Tumor	2014	25
Discovery of T-1101 tosylate as a first-in-class clinical candidate for Hec1/Nek2 inhibition in cancer therapy Shih‐Hsien Chuang, Ying-Shuan E. Lee, Lynn Y.L. Huang, European Journal of Medicinal Chemistry First-in-class Clinical CandidateT-1101 TosylateHec1/nek2 InhibitionMedicineOncogenic Agent	2020	20
Activity of a Novel Hec1-Targeted Anticancer Compound against Breast Cancer Cell Lines <i>In Vitro</i> and <i>In Vivo</i> Lynn Y.L. Huang, Chia‐Chi Chang, Ying-Shuan Lee, Molecular Cancer Therapeutics Breast OncologyNanotherapeuticsMdr GeneChemoprevention StrategyDrug Targeting	2014	19
Rational design, engineer, and characterization of a novel pegylated single isomer human arginase for arginine depriving anti-cancer treatment Kuo-Ming Yu, Tammy Pui-shi Pang, Murray J. Cutler, Life Sciences Medicinal ChemistryEngineeringBiochemistryRational DesignDrug Discovery	2020	15

Page 1